Albert A. Hagege
Experienced in Cardiomyopathy Due to Anthracyclines

Albert A. Hagege

Paris, FR 
Experienced in Cardiomyopathy Due to Anthracyclines
Paris, FR 
OverviewLocationsClinical Research

Overview

Albert Hagege practices in Paris, France. Mr. Hagege is rated as an Experienced expert by MediFind in the treatment of Cardiomyopathy Due to Anthracyclines. His top areas of expertise are Mitral Valve Prolapse, Hypertrophic Cardiomyopathy (HCM), Cardiomyopathy, and Fabry Disease.

His clinical research consists of co-authoring 112 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Cardiomyopathy Due to Anthracyclines.

Gender
Male

Locations

Paris, France
Other Locations
Georges, France
Villeurbanne, 69100, France
Nancy, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Enrollment Status: Completed
Publish Date: October 04, 2021
Intervention Type: Drug
Study Phase: Phase 3
French Observatory of Familial Hypercholesterolemia in Cardiology
French Observatory of Familial Hypercholesterolemia in Cardiology
Enrollment Status: Terminated
Publish Date: August 07, 2019
A Randomized, Double-blind, Multi-centre Study to Assess Safety and Efficacy of Incremental Doses of QGC001 in Patients With NYHA Class II/III Chronic Heart Failure (HF) With Left Ventricular Systolic Dysfunction Versus Placebo.
A Randomized, Double-blind, Multi-centre Study to Assess Safety and Efficacy of Incremental Doses of QGC001 in Patients With NYHA Class II/III Chronic Heart Failure (HF) With Left Ventricular Systolic Dysfunction Versus Placebo.
Enrollment Status: Terminated
Publish Date: October 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

112 Total Publications

Repair of infarcted myocardium by skeletal muscle-derived mesenchymal stromal cells delivered by a bioprinted collagen patch.
Repair of infarcted myocardium by skeletal muscle-derived mesenchymal stromal cells delivered by a bioprinted collagen patch.
Journal: Stem cell research & therapy
Published: April 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hagege's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile